Sagent Pharmaceuticals (SGNT) Misses Q2 EPS by 6c
Tweet
Share
E-mailGet Alerts SGNT Hot Sheet
Join SI Premium – FREE
Sagent Pharmaceuticals (NASDAQ: SGNT) reported Q2 EPS of ($0.01), $0.06 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $77.3 million versus the consensus estimate of $83.28 million.
For earnings history and earnings-related data on Sagent Pharmaceuticals (SGNT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- SeaStar Medical (ICU) Misses Q1 EPS by 4c
- Stantec (STN) Tops Q2 EPS by 47c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
